RET and lung carcinoma: A retrospective analysis of 551 lung cancer patients from 24 centers in 10 countries revealed that in the 16 patients with RET fusion-positive NSCLC, ICI monotherapy achieved an ORR of only 6% and a median PFS of 2.1 months, which were overall lower compared to the responses of patients with other driver mutations such as EGFR, KRAS, and BRAF (22).